Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Fallopian Tube Neoplasms 16Ovarian Neoplasms 14Triple Negative Breast Neoplasms 9Lung Neoplasms 9Brenner Tumor 9Breast Neoplasms, Male 9Adenocarcinoma of Lung 9Adenocarcinoma, Bronchiolo-Alveolar 8Unspecified Adult Solid Tumor, Protocol Specific 7Endometrial Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Melanoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Esophageal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Oropharyngeal Neoplasms 2Endometrial Adenocarcinoma 2Carcinoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Mucinous × Taxes × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡